{"entity":{"id":"nct06959589","kind":"trial","name":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met","aka":["cruciall"],"tldr":"A phase 2 trial in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06959589 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 50 participants, started 2025-05-22 and due to reach its primary completion in 2027-05-31. Interventions recorded: IBI351, cetuximab β combined with FOLFIRI. Conditions listed: Colorectal Cancer Metastatic; KRAS G12C Mutation. Primary outcome: ORR. Colorectal eligibility wording from the registry: \"The patient must have histologically and/or cytologically confirmed metastatic colorectal cancer (stage IV) 3\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06959589","url":"https://clinicaltrials.gov/study/NCT06959589"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","kras-g12c-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06959589","phase":"2","setting":"An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06959589/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}